Salesforce invests $2.7 billion to acquire startup Cresta
The Block
1h ago
Ai Focus
Salesforce Announces Plan to Acquire AI, a Nine-Year-Old Automated Call Center Software Vendor Cresta on Monday. According to informed sources, the transaction is valued at $2.7 billion. Cresta originated from Stanford University's Artificial Intelligence Laboratory and was valued at $1.6 billion after its Series C financing in 2022.
Helpful
No.Help

Salesforce continues its recent wave of acquisitions by taking over a startup call center company, AI, which originated from Stanford University's artificial intelligence laboratory.

Salesforce continues to operate in acquisition mode, and on Monday, the company announced plans to acquire AI, a call center automation software vendor that was established nine years ago, from Cresta. Salesforce did not disclose the transaction amount to the public, but according to an informed source, the transaction price for this acquisition is $2.7 billion.

This acquisition reflects that this software giant is making significant efforts to expand its customer service business. This business is facing competitive pressure from startups such as Sierra. Sierra was founded by Brett Taylor, former co-CEO of Salesforce. As early as September this year, Salesforce completed the acquisition of Fin, a customer service chatbot manufacturer, for $3.6 billion.

Cresta originated from a research project at Stanford University's Artificial Intelligence Laboratory and was officially established in 2017. The co-founders included computer scientist Sebastian Thrun, who led several AI projects at Google, as well as Tim and Zaid Inam. After completing a Series C financing round in 2022, the startup was valued at $1.6 billion, but its current valuation is not known.

According to PitchBook data, Cresta has raised a total of over $280 million in financing, with investors including Andreessen Horowitz, Sequoia Capital, Tiger Global Fund, and other institutions.

Spokespersons for Salesforce and Cresta have not yet commented on this.

Tip
$0
Like
0
Save
0
Views 39
HQYC reminds readers to view blockchain rationally, stay aware of risks, and beware of virtual token issuance and speculation. All content on this site represents market information or related viewpoints only and does not constitute any form of investment advice. If you find sensitive content, please click“Report”,and we will handle it promptly。
Submit
Comment 0
Hot
Latest
No comments yet. Be the first!
Related
Ethereum is a "tokenized toll road": Reasons why Joseph Chalom is bullish on ETH
SharpLink CEO Joseph Chalom stated that the long-term logic of ETH is strengthening, and the key is no longer a single catalyst, but rather the speed of blockchain on Wall Street. He proposed three indicators for observation: the supply of stablecoins, the scale of tokenized stocks, and the volume of payment transactions between AI agents.
Coinpedia
·2026-11-03 19:35:50
0
Clarivate Announces Third Quarter 2026 Results, Calling It a Clear Path to Value Creation
Clarivate releases third-quarter results as of September 30, 2026. The company stated that driven by portfolio adjustments and AI-initiated innovation, recurring organic revenue growth has improved, and the annual contract value ( ACV ) of its intellectual property business has resumed growth. Additionally, the company completed the divestiture of its life sciences and healthcare business on October 6 and updated its financial outlook for 2026.
PR Newswire
·2026-11-03 19:24:26
13
Waters Corporation Announces Financial Results for the Third Quarter of 2026
Waters Corporation Announces Financial Results for the Third Quarter of 2026: Revenue of $1.767 Billion, Adjusted Earnings Per Share of $4.10; The Company Upsits Its Annual Revenue and Adjusted Earnings Per Share Guidance for 2026, and Indicates That It Will Provide a Growth Framework for 2027 During the Earnings Call.
PR Newswire
·2026-11-03 19:15:16
19
Clarivate Announces Third Quarter 2026 Results, Claiming to Have Paved a Clear Path for Value Creation
Clarivate Announces Third Quarter 2026 Results, Says Recurrent Organic Revenue Growth Improves Driven by Portfolio Adjustment and AI-Driven Innovation; Intellectual Property Business ACV Resumes Positive Growth; Company Also Updates 2026 Financial Prospects and Completes Sale of Life Sciences and Healthcare Business.
PR Newswire
·2026-11-03 19:15:14
18
Little-known biotech company Genmab sees success with high-risk cancer treatment bets; stock price doubles in three months
Danish biotech company Genmab has seen its stock price double within three months following a series of successful cancer drug trials. The company stated that these breakthroughs have provided new momentum for its strategy to shift from relying on royalty income to taking more control over the ownership and sales revenue of its own developed drugs.
CNBC
·2026-11-03 19:15:12
20
View More